Glaukos Corp's stock price decreased by 5.88% as it crossed below its 5-day SMA, indicating a significant downward movement in its share value.
The decline in Glaukos Corp's stock is attributed to sector rotation, as the broader market, represented by the Nasdaq-100 and S&P 500, experienced gains of 0.98% and 0.49%, respectively. This suggests that investors are reallocating their investments away from Glaukos and similar stocks towards sectors that are performing better in the current market environment.
This movement may reflect a shift in investor sentiment, where funds are being directed towards more favorable sectors, potentially impacting Glaukos Corp's future performance unless there are changes in market dynamics or company-specific developments.
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GKOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GKOS is 127.08 USD with a low forecast of 72.00 USD and a high forecast of 165.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
0 Hold
1 Sell
Strong Buy
Current: 119.070
Low
72.00
Averages
127.08
High
165.00
Current: 119.070
Low
72.00
Averages
127.08
High
165.00
Wells Fargo
Overweight
maintain
$122
2026-01-28
New
Reason
Wells Fargo
Price Target
$122
AI Analysis
2026-01-28
New
maintain
Overweight
Reason
Wells Fargo notes that Glaukos has announced FDA approval of its repeat dosing label for iDose, in line with the firm's expectations. Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122.
BTIG
Buy
maintain
$123 -> $131
2026-01-28
New
Reason
BTIG
Price Target
$123 -> $131
2026-01-28
New
maintain
Buy
Reason
BTIG raised the firm's price target on Glaukos to $131 from $123 and keeps a Buy rating on the shares after the company announced FDA approval allowing for repeat treatments of iDose. Glaukos now has a much broader label for iDose than the prior label, which was limited to one iDose per eye, the analyst tells investors in a research note. BTIG believes the approval gives the company "significant optionality" in the interventional glaucoma space.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GKOS
Unlock Now
Stifel
Buy
maintain
$115 -> $160
2026-01-22
Reason
Stifel
Price Target
$115 -> $160
2026-01-22
maintain
Buy
Reason
Stifel raised the firm's price target on Glaukos to $160 from $115 and keeps a Buy rating on the shares. The firm's Epioxa survey work was better-than-anticipated, says the analyst, who revamped the firm's Epioxa sales build and arrives at 2027/2028 U.S. Epioxa sales estimates of $272M and $571M, respectively. Holding all else equal, this would drive a revenue growth acceleration from 25% year-over-year in 2026 to 46% and 45% in 2027 and 2028, respectively, the analyst tells investors.
Goldman Sachs
Buy
maintain
$112 -> $138
2026-01-09
Reason
Goldman Sachs
Price Target
$112 -> $138
2026-01-09
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Glaukos to $138 from $112 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
